Patients with arterial hypertension and obesity: targeting biomarkers as a personalised therapeutic approach
This literature review focuses on the treatment of patients with arterial hypertension (AH) and obesity, from the point of view of personalised medicine (PM). One of the PM approaches is the use of biochemical markers which reflect normal and pathologic processes in the human body, as well as the pr...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«FIRMA «SILICEA» LLC
2013-06-01
|
| Series: | Российский кардиологический журнал |
| Subjects: | |
| Online Access: | https://russjcardiol.elpub.ru/jour/article/view/394 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850029148638019584 |
|---|---|
| author | T. E. Morozova E. R. Latyipova |
| author_facet | T. E. Morozova E. R. Latyipova |
| author_sort | T. E. Morozova |
| collection | DOAJ |
| description | This literature review focuses on the treatment of patients with arterial hypertension (AH) and obesity, from the point of view of personalised medicine (PM). One of the PM approaches is the use of biochemical markers which reflect normal and pathologic processes in the human body, as well as the presence of a disease or the response to a treatment. In patients with AH and obesity, antihypertensive medications should also affect the levels of biomarkers. This requirement is met by perindopril, an angiotensin-converting enzyme (ACE) inhibitor with high tissue specificity. Pathogenetic therapy with perindopril provides an opportunity to target the biomarkers of adipokine activity, endothelial dysfunction, inflammation, and other processes. |
| format | Article |
| id | doaj-art-8167d5a3fcae49c19f90ac1d913ce237 |
| institution | DOAJ |
| issn | 1560-4071 2618-7620 |
| language | Russian |
| publishDate | 2013-06-01 |
| publisher | «FIRMA «SILICEA» LLC |
| record_format | Article |
| series | Российский кардиологический журнал |
| spelling | doaj-art-8167d5a3fcae49c19f90ac1d913ce2372025-08-20T02:59:37Zrus«FIRMA «SILICEA» LLCРоссийский кардиологический журнал1560-40712618-76202013-06-0103949910.15829/1560-4071-2013-3-94-99394Patients with arterial hypertension and obesity: targeting biomarkers as a personalised therapeutic approachT. E. Morozova0E. R. Latyipova1I. M. Sechenov First Moscow State Medical University, Department of Clinical Pharmacology and Pharmacotherapy, Post-diploma Medical Education Faculty, Moscow, RussiaI. M. Sechenov First Moscow State Medical University, Department of Clinical Pharmacology and Pharmacotherapy, Post-diploma Medical Education Faculty, Moscow, RussiaThis literature review focuses on the treatment of patients with arterial hypertension (AH) and obesity, from the point of view of personalised medicine (PM). One of the PM approaches is the use of biochemical markers which reflect normal and pathologic processes in the human body, as well as the presence of a disease or the response to a treatment. In patients with AH and obesity, antihypertensive medications should also affect the levels of biomarkers. This requirement is met by perindopril, an angiotensin-converting enzyme (ACE) inhibitor with high tissue specificity. Pathogenetic therapy with perindopril provides an opportunity to target the biomarkers of adipokine activity, endothelial dysfunction, inflammation, and other processes.https://russjcardiol.elpub.ru/jour/article/view/394arterial hypertensionantihypertensive treatmentobesitypersonalised medicinebiomarkersleptin, adiponectinendothelial dysfunctioninflammation markersinsulin resistanceangiotensin-converting enzyme inhibitorperindoprilprestarium a |
| spellingShingle | T. E. Morozova E. R. Latyipova Patients with arterial hypertension and obesity: targeting biomarkers as a personalised therapeutic approach Российский кардиологический журнал arterial hypertension antihypertensive treatment obesity personalised medicine biomarkers leptin, adiponectin endothelial dysfunction inflammation markers insulin resistance angiotensin-converting enzyme inhibitor perindopril prestarium a |
| title | Patients with arterial hypertension and obesity: targeting biomarkers as a personalised therapeutic approach |
| title_full | Patients with arterial hypertension and obesity: targeting biomarkers as a personalised therapeutic approach |
| title_fullStr | Patients with arterial hypertension and obesity: targeting biomarkers as a personalised therapeutic approach |
| title_full_unstemmed | Patients with arterial hypertension and obesity: targeting biomarkers as a personalised therapeutic approach |
| title_short | Patients with arterial hypertension and obesity: targeting biomarkers as a personalised therapeutic approach |
| title_sort | patients with arterial hypertension and obesity targeting biomarkers as a personalised therapeutic approach |
| topic | arterial hypertension antihypertensive treatment obesity personalised medicine biomarkers leptin, adiponectin endothelial dysfunction inflammation markers insulin resistance angiotensin-converting enzyme inhibitor perindopril prestarium a |
| url | https://russjcardiol.elpub.ru/jour/article/view/394 |
| work_keys_str_mv | AT temorozova patientswitharterialhypertensionandobesitytargetingbiomarkersasapersonalisedtherapeuticapproach AT erlatyipova patientswitharterialhypertensionandobesitytargetingbiomarkersasapersonalisedtherapeuticapproach |